tbuckley/cabot-search huggingface dataset:
Daily pain in adults with sickle cell disease-a different perspective
Authors: Charlotte F. J. van Tuijn, Joep W. R. Sins, Karin Fijnvandraat, Bart J. Biemond
Journal: American Journal of Hematology (2016)

Previous reports demonstrated that patients with sickle cell disease (SCD) experience pain on more than half of the observed days. Yet, these high incidences do not seem to match observations in our population. In this prospective cohort study, we aimed to assess the frequency and characteristics of daily, self-reported pain among adult SCD patients in the Netherlands. Consecutive patients were enrolled during routine outpatient visits and followed up to 6 months. A total of 55 patients completed 5,982 diary observation days. Median age was 27 years (IQR 23-43). Patients reported SCD related pain on 17% of the observed days; on 13% of these days this pain was not defined as a painful crisis, while 3% was reported as a painful crisis but managed at home, and on 1% of the observed days patients were admitted to the hospital. Analgesics were used on 52% of days with pain with a relatively infrequent use of oral opioids (9% of pain days). This first European study on pain in SCD indicates that pain appears to be significantly less frequent in our population as compared to previous study cohorts from the United States, and may be more representative for current SCD populations in other Western countries. Besides a more widespread use of hydroxycarbamide in modern disease management, differences in organization and accessibility of healthcare between countries may also explain this discrepancy.
Ristocetin-Induced Platelet Aggregation for Monitoring of Bleeding Tendency in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia
Authors: Lukas Kazianka, Christa Drucker, Cathrin Skrabs, Philipp Bernhard Staber, Edit Anna Porpaczy, Christine Einberger, Marion Heinz, Alexander Hauswirth, Ingrid Pabinger, Peter Quehenberger, Bernd Jilma, Ulrich Jaeger
Journal: Blood (2015)
SP0008 Under What Conditions May Long-Term Glucocorticoids Have A Good Benefit-Risk Ratio?
Authors: F. Buttgereit
Journal: Annals of the Rheumatic Diseases (2016)

Although there is convincing evidence for the beneficial effects of glucocorticoids at low dosages to treat rheumatoid arthritis and other rheumatic diseases, the potential harms lead patients and physicians to be grouped as glucocorticoid “supporters”, “opponents” or “neutrals” (i.e. people not favouring any pro or con position, perhaps the majority). In detail, patients are usually aware of both benefits and risks of glucocorticoid therapy. There is, however, sometimes even a certain imbalance favouring the risks over the benefits. This may be reflected in serious concerns about adverse effects and sometimes even refusal to take glucocorticoid treatment which hinders optimal treatment. Also with regard to medical doctors, nobody really questions the efficacy of these drugs, but the splitting up into the mentioned groups is primarily driven by safety concerns. And indeed, every group has their good arguments. To approach this problem, a EULAR Task Force was convened in order to achieve consensus on specific conditions where long-term glucocorticoid therapy has an acceptably low risk of harm in the treatment of chronic inflammatory rheumatic diseases (Strehl et al., Ann Rheum Dis, 2016). After a systematic literature search, the evidence on the four most worrisome adverse effects of glucocorticoid therapy (osteoporosis, hyperglycaemia/diabetes mellitus, cardiovascular diseases, and infections) was critically reviewed. Robust evidence on the risk of harm of long-term glucocorticoid therapy was often lacking since relevant study results were often either missing, contradictory, or at a high risk of bias. The group agreed that the risk of harm is low for the majority of patients at long-term dosages of ≤5mg prednisone equivalent per day, whereas at dosages of &gt;10mg/d the risk of harm is elevated. At dosages between &gt;5 and ≤10mg/d, patient-specific characteristics including protective and/or risk factors need consideration when estimating the risk of harm. In conclusion, the level of harm of glucocorticoids depends on both dose and patient-specific parameters. General, disease and glucocorticoid associated risk factors but also protective factors like a healthy lifestyle should be taken into account when evaluating the actual and future risk. <h3>Disclosure of Interest</h3> F. Buttgereit Grant/research support from: Horizon Pharma, Consultant for: Horizon Pharma, Mundipharma, Pfizer, Speakers bureau: Horizon Pharma, Mundipharma, Pfizer
Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients
Authors: Fabio Efficace, Paola Fazi, Cristina Santoro, Gianluca Gaidano, Francesco Cottone, Alessandra Borchiellini, Monica Carpenedo, Maria Pina Simula, Valeria Di Giacomo, Ivana Pierri, Francesco Nobile, Francesco Rodeghiero, Laura Scaramucci, Alessandro Rambaldi, Nicola Cascavilla, Fabio Forghieri, Annamaria Petrungaro, Paolo Ditonno, Giorgio La Nasa, Sonia Cirrincione, Franco Mandelli, Maria Gabriella Mazzucconi
Journal: Blood (2015)
Prognostic Impact of Cytogenetics and Early Response and Efficacy of Sequential High-Dose AraC and Idarubicin (S-HAI) in Patients with Refractory and Relapsed Acute Myeloid Leukemia (AML): Results of a Prospective Study.
Authors: Wolfgang Kern, Hubert Serve, Peter Staib, Christa Kerschgens, Anett Matylis, Karin Tischmann, Christoph Huber, Wolf D. Hirschmann, Hartmut Eimermacher, Johann G. Lange, Anke Zumsprekerl, Georg Maschmeyer, Michael Unterhalt, Jörn Ohnesorge, Maria C. Sauerland, Wolfgang Berdel, Thomas Büchner, Torsten Haferlach, Claudia Schoch, Wolf D. Ludwig, Wolfgang Hiddemann
Journal: Blood (2004)
AB1119-HPR Evaluation of The Podiatric Need of People with Inflammatory Arthritis in Singapore
Authors: K. Carter, M. Lahiri, P. Cheung, A. Santosa, K. Rome
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Foot problems are common in people with inflammatory arthritis [1]. International guidelines recommend referral to podiatry of all people with rheumatic disease and foot problems [2–4]. Areas covered in the guidelines include access to foot care, assessment and review, foot orthoses and footwear. It is known that access to podiatry services varies between, and even within, countries [5,6]. Such information relating to access and uptake to podiatry services in Singapore for people with inflammatory arthritis is not available. <h3>Objectives</h3> To assess the referral rate from a hospital rheumatology department to podiatry services, and the level of satisfaction of referred patients with their podiatry assessment and interventions. <h3>Methods</h3> People with inflammatory arthritis were recruited from the rheumatology outpatient clinic of a large public hospital in Singapore. Disease and clinical characteristics were recorded. Participants were asked questions relating to foot problems, access to podiatry services and their perceived usefulness of foot assessment and/or interventions in alleviating their foot symptoms. A footwear assessment was also conducted. <h3>Results</h3> 101 patients with inflammatory arthritis were recruited, of which 50% were female. The mean age was 52±15 years, and the mean disease duration was 9.3±0.3 years. The majority (86%, n=78) of participants with foot problems had discussed their foot symptoms with their rheumatologist, though only 21% of participants (n=21) were referred to a podiatrist. Of these, most (n=17, 81%) reported the foot assessments and the podiatric interventions as having been useful (n=15, 71%); 13 (62%) had been prescribed foot orthoses, of which only 9 reported finding them to be beneficial in reducing foot pain. Over 50% of all the study participants (n=51) reported problems with footwear. Only 32 people had correctly fitting footwear. No participants had been issued with therapeutic footwear. <h3>Conclusions</h3> Though the majority of people with inflammatory arthritis reported foot problems few received a referral to podiatry. This study is the first to identify an unmet need in Singapore in the podiatric treatment of foot problems in people with inflammatory arthritis, and the under utilization of podiatry service. The results provide a foundation for further study to identify and provide solutions to overcome barriers preventing the utilization of podiatry services. <h3>References</h3> Brenton-Rule A, et al. J Foot Ankle Res 2014; 7:36. Gossec L, et al. Joint Bone Spine 2006; 73:396–402. Forestier R, et al. Joint Bone Spine 2009; 76:691–698. National Institute of Clinical Effectiveness 2013. [http://www.nice.org.uk/Guidelines/CG79] Rome K, et al. NZ Med J 2013; 126:70–77. Williams A, Bowden A. Foot 2004; 14:154–158. <h3>Disclosure of Interest</h3> None declared
Molecular Monitoring and Stepwise Preemptive Therapy to Prevent Epstein-Barr Virus-Associated Diseases After Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Li Xuan, Ke Zhao, Fen Huang, Meiqing Wu, Xiao Zhai, Fuhua Zhang, Hongsheng Zhou, Zhiping Fan, Jing Sun, Qifa Liu
Journal: Blood (2012)
Стан панкреатобіліарної системи та інтестинальної мікрофлори в дітей із неалкогольною жировою хворобою печінки
Authors: N.Yu. Zavgorodnya, O.Yu. Lukianenko, I.S. Konenko
Journal: GASTROENTEROLOGY (2016)

Неалкогольна жирова хвороба печінки (НАЖХП) об’єднує такі патологічні стани, як стеатоз печінки, неалкогольний стеатогепатит, фіброз та цироз печінки, і вважається печінковим проявом метаболічного синдрому. Не лише печінка стає органом-мішенню в разі формування метаболічного синдрому: доведена можливість розвитку стеатозу жовчного міхура, підшлункової залози та біліарного тракту. Жирова інфільтрація панкреатобіліарного тракту асоційована з порушенням процесів травлення, що супроводжується розвитком дисбіотичних змін та інтестинальних розладів. Зміни кишкової мікробіоти, зі свого боку, можуть індукувати системну запальну реакцію та сприяти прогресуванню НАЖХП. Мета: вивчити структурно-функціональний стан панкреатобіліарної системи та зміни тонкокишечної мікрофлори в дітей із НАЖХП. Методи. У 34 дітей із патологією шлунково-кишкового тракту визначали контрольований параметр ультразвукового затухання із використанням апарата FibroScan. Оцінку функціонального стану біліарного тракту здійснювали за допомогою ультразвукового дослідження органів черевної порожнини із пробним сніданком для визначення скоротливої функції жовчного міхура й тонусу сфінктера Одді. Для характеристики стану тонкокишкової мікробіоти проводили водневий дихальний тест із навантаженням глюкозою або лактозою. Розподіл дітей на групи відбувався згідно з даними транзієнтної еластрографії печінки (FibroScan): контрольну групу становив 21 пацієнт без стеатозу печінки, основну групу — 13 пацієнтів із стеатозом печінки. Результати. Діти з неалкогольною жировою хворобою печінки мали ознаки ураження не тільки печінки, але й жовчовивідних шляхів та підшлункової залози. Патологія жовчовивідних шляхів у пацієнтів із НАЖХП частіше проявлялась у вигляді гіпотонії сфінктера Одді та гіпокінезії жовчного міхура. Ураження підшлункової залози в дітей із НАЖХП може пояснюватися наявністю функціонального розладу сфінктера Одді та проявами стеатозу підшлункової залози. Зміни в стані мікрофлори тонкої кишки спостерігалися у 27,6 % обстежених хворих. Синдром надмірного бактеріального росту вірогідно частіше відмічався в групі хворих зі стеатозом печінки.
PTU-148 Endoscopic Surveillance in Dysplastic Barrett’s Oesophagus (BO)
Authors: HN Alastal, K Nemeth, M Rashid, J Kenkre, A Rasheed
Journal: Gut (2016)

<h3>Introduction</h3> Barrett’s oesophagus is a premalignant condition and patients with BO undergo surveillance to detect early cancerous changes. Our aim is to assess the effectiveness of endoscopic surveillance in detecting progression to High-Grade Dysplasia (HGD) or Oesophageal Adenocarcinoma (OAC). <h3>Methods</h3> All BO cases coded in our histopathology database as dysplastic BO during the period from 2005 to 2015 were identified. The documented endoscopy reports were matched with histopathology reports. A retrospective database was then constructed including demographics, pathological features, modes and rates of follow-up and pathological progression. Our surveillance practice was also audited against the 2013 BSG guidance. <h3>Results</h3> A total of 73 cases were identified as dysplastic BO; the cohort consisted of 55 males and 18 females. (Mean age: 70.1 years, range: from 51.4 to 88.4 years). 47/73 (64%) had hiatus hernia. Intestinal metaplasia was reported in 71/73 cases. 14/73 cases (19%) progressed to HGD or OAC. Five patients offered oesophagectomy, while the others had surveillance (3), endoscopic mucosal resection (3) or chemo/radiotherapy (3). 4/14 cases were noted to have either prevalent HGD/OAC (3) or interval OAC (1) and hence excluded from the audit. Five cases did not have any follow up either because of the patient’s noncompliance (2) or the endoscopists’ recommendation (3). 64 (88%) cases had complete data and constituted the cohort for assessment of compliance with BSG guidance. Mean follow up was 4.67 years. The total number of endoscopies performed during this period was 250. 65.2% (163/250) of endoscopies were compliant with BSG follow up protocol. Only 18/130 endoscopies (13.8%) provided both C and M measurements of Prague measurement. Average BO length based on 113 endoscopies was 5.3 cm. The mean expected number of biopsies was 11.0 while the actual number of biopsies taken was 7.3 (66.1%). There was some discordance between the number of biopsies mentioned by endoscopists and the number of biopsies counted by pathologists in 72 available endoscopic and pathological data. Overall compliance with BSG protocol in terms of follow up, Prague criteria and sampling count was 48.4% in total. <h3>Conclusion</h3> The surveillance program detected progression to HGD or OAC in 10 cases (14.5%). Compliance with BSG protocol in terms of follow up, Prague criteria and sampling count was noted in 48.4%. Further adherence with the BSG guidelines is needed to improve the surveillance program. <h3>Disclosure of Interest</h3> None Declared
Efficacy of four different regimens in 64 mantle-cell lymphoma cases
Authors: I Teodorovic, S Pittaluga, Johanna Kluin-Nelemans, J H Meerwaldt, A Hagenbeek, M van Glabbeke, R Somers, L Bijnens, E M Noordijk, C D Peeters
Journal: Journal of Clinical Oncology (1995)
Targeting MUC1 as a Marker for Myeloid Leukemia Stem Cells by DC/AML Fusions.
Authors: Jacalyn Rosenblatt, Zekui Wu, Corrine Lenahan, Adam Bissonnette, Baldev Vasir, Kenneth Miller, Robin Joyce, James Levine, Ilene Galinsky, Richard Stone, Donald Kufe, David Avigan
Journal: Blood (2007)
Multidimensional Flow Cytometric (MFC) Analysis of the Immune System of Multiple Myeloma (MM) Patients Achieving Long Term Disease Control
Authors: Roberto J. Pessoa Magalhaes, María-Belén Vidriales, Bruno Paiva, Maria-Victoria Mateos, Norma C. Gutierrez, Ramón García-Sanz, Juan F Blanco, Jose Hernández, Natalia de las Heras, Joaquin Martinez, Elaine Sobral Costa, Angelo Maiolino, M. Nucci, Javier De La Rubia, Juan-Jose Lahuerta, Alberto Orfao, Jesús F. San Miguel
Journal: Blood (2011)
Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator–inducible T-cell costimulator ligand interaction
Authors: Diamanda Rigas, Gavin Lewis, Jennifer L. Aron, Bowen Wang, Homayon Banie, Ishwarya Sankaranarayanan, Lauriane Galle-Treger, Hadi Maazi, Richard Lo, Gordon J. Freeman, Arlene H. Sharpe, Pejman Soroosh, Omid Akbari
Journal: Journal of Allergy and Clinical Immunology (2016)
Healthy Donor Whole Bone Marrow Cells Preconditioned With Myeloma Patient Serum Support Long-Term Survival Of Primary Myeloma and Reveal Altered Microenvironmental Pathways
Authors: Rakesh Bam, Sathisha Upparahalli Venkateshaiah, Xin Li, Sharmin Khan, Wen Ling, Randal S Shelton, Joshua Epstein, Bart Barlogie, Shmuel Yaccoby
Journal: Blood (2013)
Establishment of Bioluminescence Imaging Based Leukemia In Vivo Model for Preclinical Testing
Authors: Myoung Woo Lee, Hye Jin Kim, Dae Seong Kim, Meong Hi Son, Soo Hyun Lee, Hye Lim Jung, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo
Journal: Blood (2011)
Heart Failure Stages Among Older Adults in the Community
Authors: Amil M. Shah, Brian Claggett, Laura R. Loehr, Patricia P. Chang, Kunihiro Matsushita, Dalane Kitzman, Suma Konety, Anna Kucharska-Newton, Carla A. Sueta, Thomas H. Mosley, Jacqueline D. Wright, Joseph Coresh, Gerardo Heiss, Aaron R. Folsom, Scott D. Solomon
Journal: Circulation (2016)

Background: Although heart failure (HF) disproportionately affects older adults, little data exist regarding the prevalence of American College of Cardiology/American Heart Association HF stages among older individuals in the community. Additionally, the role of contemporary measures of longitudinal strain and diastolic dysfunction in defining HF stages is unclear. Methods: HF stages were classified in 6118 participants in the Atherosclerosis Risk in Communities study (67–91 years of age) at the fifth study visit as follows: A (asymptomatic with HF risk factors but no cardiac structural or functional abnormalities), B (asymptomatic with structural abnormalities, defined as left ventricular hypertrophy, dilation or dysfunction, or significant valvular disease), C1 (clinical HF without prior hospitalization), and C2 (clinical HF with earlier hospitalization). Results: Using the traditional definitions of HF stages, only 5% of examined participants were free of HF risk factors or structural heart disease (Stage 0), 52% were categorized as Stage A, 30% Stage B, 7% Stage C1, and 6% Stage C2. Worse HF stage was associated with a greater risk of incident HF hospitalization or death at a median follow-up of 608 days. Left ventricular (LV) ejection fraction was preserved in 77% and 65% in Stages C1 and C2, respectively. Incorporation of longitudinal strain and diastolic dysfunction into the Stage B definition reclassified 14% of the sample from Stage A to B and improved the net reclassification index ( P =0.028) and integrated discrimination index ( P =0.016). Abnormal LV structure, systolic function (based on LV ejection fraction and longitudinal strain), and diastolic function (based on e’, E/e’, and left atrial volume index) were each independently and additively associated with risk of incident HF hospitalization or death in Stage A and B participants. Conclusions: The majority of older adults in the community are at risk for HF (Stages A or B), appreciably more compared with previous reports in younger community-based samples. LV ejection fraction is robustly preserved in at least two-thirds of older adults with prevalent HF (Stage C), highlighting the burden of HF with preserved LV ejection fraction in the elderly. LV diastolic function and longitudinal strain provide incremental prognostic value beyond conventional measures of LV structure and LV ejection fraction in identifying persons at risk for HF hospitalization or death.
PARE0017 Eular Young Pare: The Voice of Young People with Rheumatic Diseases across Europe
Authors: J. Andersen, S. Stones, P. Balazova, L. Van Nieuwkoop, T. Papastavrou, N. Caeyers, F. Klett
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The group of Young Patients with Arthritis/Rheumatism in Europe (PARE) in EULAR, the European League Against Rheumatism, is a network of young people, from across Europe, living with a rheumatic or musculoskeletal disease (RMD) and working with a patient organisation in their country. They volunteer their time to represent young people with RMDs within EULAR PARE, advocating for better care, communication and quality of life for individuals, under 35, across Europe. <h3>Objectives</h3> When the group was established, objectives were designed to: (1) establish and strengthen national RMD youth groups across Europe; (2) create and support the European network of RMD youth groups to exchange best practices; (3) empower youth leaders; and (4) ensure that the voice of young people with RMDs is heard on all levels in society. <h3>Methods</h3> EULAR Young PARE are actively involved in local, national and international activities to support young people with RMDs. Members of EULAR Young PARE developed an action plan to communicate and promote their work, embedding the youth perspective into and supporting all EULAR PARE activities. <h3>Results</h3> A strong voice of young people, especially at the Annual European Conference of PARE, has been established, with topics delivered and dedicated to the needs of young people. All PARE activities and projects now entail a young person living with an RMD, feeding back into the Young PARE working group. Furthermore, strengthening collaboration with the EMEUNET network is a leading example of how we learn together. <h3>Conclusions</h3> Young PARE have moved forward considerably over the last twelve months, gathering and sharing information about the ways that young people with RMDs are supported in European countries. Now, EULAR Young PARE is continuing to unite patient organisations across Europe, helping to raise awareness and make a difference to young people living with RMDs while challenges remain. It is important to keep the network sustainable, and EULAR Young PARE committed to working on this over the coming years. <h3>References</h3> EULAR Young PARE. Available from: http://www.youngpare.org[Accessed 13 December 2015]. <h3>Acknowledgement</h3> Special thanks to EULAR and EULAR PARE for supporting the vision of EULAR Young PARE. EULAR Young PARE would also like to acknowledge all of the patient organisations that they continue to work with. <h3>Disclosure of Interest</h3> None declared
FRI0178 Anti-Etanercept Antibodies and Etanercept Leves Levels in Rheumatoid Arthritis Patients Treated with Low and Full-Dose Etanercept in Das28 Remission: Table 1.
Authors: F. Ometto, M. Beggio, L. Friso, D. Astorri, B. Raffeiner, C. Botsios, L. Bernardi, R. Padoan, L. Punzi, A. Ghiraldello, A. Doria
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To investigate etanercept (ETN) serum levels and anti-etanercept antibodies (AEA) and evaluate whether ETN levels are associated with SDAI remission in rheumatoid arthritis patients in DAS28 remission treated with full-dose (25 mg twice weekly) and low-dose (25 mg once weekly) ETN. <h3>Methods</h3> We selected 70 patients in stable (≥12 months) full-dose (35) or low-dose (35) ETN, in remission (DAS28&lt;2.6 for ≥12 months) and with a treatment duration ≥5 years. AEA and basal ETN levels were tested by ELISA. A cut-off &gt;142AU/ml was adopted for defining positive AEA. A concentration of ETN ≥3.1μg/mL was considered as a high ETN level [1]. Multivariate regression analysis was used to investigate whether high ETN levels were associated with SDAI remission. <h3>Results</h3> One blood sample in the low-dose group resulted inadequate. AEA were present in 1 patient in low-dose (1/34, 2.9% low-dose ETN vs 0/35, 0% full-dose ETN, p=0.507). Full-dose and a lower weight were associated with high ETN levels: 15/35, 42.9% vs 3/34, 8.8% p=0.001 and 55.0 kg (57.0;80.0) and 65.0 (51.0;69.8), p=0.014 for high and low ETN levels respectively. Lower ETN levels, low-dose and a longer low-dose duration were associated with SDAI remission but were not confirmed with multivariate regression (Table 1). <h3>Conclusions</h3> AEA are almost absent in patients in stable remission, patient with full-dose ETN and lower weight have higher ETN levels. ETN levels are not predictive of SDAI remission. <h3>References</h3> Daïen CI, Daïen V, Parussini E, et al. Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study. J Rheumatol 2012.39(8):1533–8. <h3>Disclosure of Interest</h3> None declared